Please login to the form below
chronic kidney disease
This page shows the latest chronic kidney disease news and features for those working in and with pharma, biotech and healthcare.
NICE recommends AZ’s Forxiga for kidney disease
AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Forxiga (dapagliflozin) for the treatment of adults with chronic kidney disease (CKD). ... CKD is a long-term condition where the patient’s
Latest news
-
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
This is the third deal between the companies. In 2018, AZ signed strategic collaborations covering ION532, in apolipoprotein L1-associated chronic kidney disease and ION839, for non-alcoholic steatohepatitis (NASH). ... Eplontersen is designed to reduce
-
AstraZeneca’s Forxiga approved in Japan for the treatment of CKD
Approval was based on positive data from the phase 3 trial for chronic kidney disease. ... Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “This approval is an important step towards realising our ambition of improving outcomes
-
Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting
against placebo when added to standard of care for people with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease. ... the composite cardiovascular endpoint in patients with type 2 diabetes and chronic kidney disease.
-
FDA requests further safety trials for AZ, FibroGen’s roxadustat
of anaemia of chronic kidney disease (CKD), in both non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients. ... Cardiovascular, renal and metabolism (CVRM) is a key growth driver for AstraZeneca and is one of the company’s main disease
-
FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
A US Food and Drug Administration (FDA) advisory committee has voted against approval of AstraZeneca (AZ) and FibroGen’s roxadustat for the treatment of anaemia in chronic kidney disease (CKD) patients. ... New solutions are needed for the six million
More from news
Approximately 7 fully matching, plus 94 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... AstraZeneca's R&D centre in Cambridge, UK. Moderate to severe chronic kidney disease (CKD) is an under-recognised public health
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of
-
25 Women Leaders in UK Healthcare
The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
-
China: AstraZeneca’s new engine for growth and innovation
FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.
More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Developing a Costed Integrated Patient Scenario, such as this for chronic kidney disease, can be a powerful way of evaluating the different components in a patient’s care, and showing, in ... reinvigorate the disease-specific service improvement
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of cardiovascular diseases, hepatitis, HIV, chronic kidney disease and digestive diseases.
-
Its Know Your Numbers week
One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking
-
Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards
This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease. ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel patient campaign, designed to help
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
